Ashraf Omar Abdelaziz
A5058040580- Liver Disease Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Hepatitis C virus research
- Hepatitis B Virus Studies
- Liver Disease and Transplantation
- COVID-19 Clinical Research Studies
- Cancer, Lipids, and Metabolism
- SARS-CoV-2 and COVID-19 Research
- Long-Term Effects of COVID-19
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cardiac Structural Anomalies and Repair
- Cancer-related molecular mechanisms research
- Cardiac and Coronary Surgery Techniques
- Cardiac Valve Diseases and Treatments
- MicroRNA in disease regulation
- Systemic Lupus Erythematosus Research
- Circular RNAs in diseases
- Animal Virus Infections Studies
- Intensive Care Unit Cognitive Disorders
- Heparin-Induced Thrombocytopenia and Thrombosis
- Agriculture Market Analysis Ukraine
- Amoebic Infections and Treatments
- Cancer Mechanisms and Therapy
- Corporate Identity and Reputation
- Livestock Management and Performance Improvement
Cairo University
2016-2025
North Cumbria Integrated Care NHS Foundation Trust
2023
National Heart Institute
2015-2022
AstraZeneca (Brazil)
2021
Flatiron Health (United States)
2021
CytomX Therapeutics (United States)
2021
CASI Pharmaceuticals (United States)
2021
AstraZeneca (Finland)
2021
Incyte (United States)
2021
Exelixis (United States)
2021
BackgroundMany patients with COVID-19 have been treated plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent therapy in admitted hospital COVID-19.MethodsThis randomised, controlled, open-label, platform trial (Randomised Evaluation Therapy [RECOVERY]) is assessing several possible treatments hospitalised UK. The underway at 177 NHS hospitals from across Eligible consenting were randomly assigned (1:1) receive either usual care alone...
BackgroundAspirin has been proposed as a treatment for COVID-19 on the basis of its anti-thrombotic properties. We aimed to evaluate efficacy and safety aspirin in patients admitted hospital with COVID-19.MethodsIn this randomised, controlled, open-label, platform trial, several possible treatments were compared usual care hospitalised COVID-19. The trial took place at 177 hospitals UK, two Indonesia, Nepal. Eligible consenting adults randomly allocated 1:1 ratio either standard plus 150 mg...
BackgroundLow-dose corticosteroids have been shown to reduce mortality for patients with COVID-19 requiring oxygen or ventilatory support (non-invasive mechanical ventilation, invasive extracorporeal membrane oxygenation). We evaluated the use of a higher dose in this patient group.MethodsThis randomised, controlled, open-label platform trial (Randomised Evaluation Therapy [RECOVERY]) is assessing multiple possible treatments hospitalised COVID-19. Eligible and consenting adult clinical...
Summary Background Chronic hepatitis C virus infection is one of the most important health problems in Egypt. The Ministry Health's National Treatment Programme introduced sofosbuvir‐based therapy October 2014. Aim To assess clinical effectiveness and predictors response to SOF ‐based treatment regimens, either dual therapy, with /ribavirin ( RBV ) for 6 months or triple /peg‐ IFN ‐alfa‐2a/ 3 months, a cohort patients treated affiliated centres Methods Between 2014 end 2014, who were...
BackgroundEmpagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess safety efficacy in patients admitted hospital with COVID-19.MethodsIn randomised, controlled, open-label trial, several possible treatments are compared usual care hospitalised COVID-19. In this analysis, we eligible consenting adults who were randomly allocated 1:1 ratio either standard alone or plus oral...
More than 80% of global hepatocellular carcinoma (HCC) patients are estimated to occur in sub-Saharan Africa (SSA) and Eastern Asia. The most common risk factor HCC SSA is chronic hepatitis B virus (HBV) infection, with the incidence highest West Africa. HBV highly endemic perpetuated by incomplete adherence birth dose immunization, lack longitudinal follow-up care, impaired access antiviral therapy. may directly cause through somatic genetic alterations or indirectly altered liver function...
Abstract Objectives This RCT aimed to evaluate the effect of topical Rebamipide (regular and nanoparticulated) in comparison Clobetasol propionate management methotrexate-induced oral ulcers rheumatoid arthritis patients. Materials methods Patients were divided randomly into three parallel arms: 1% Rebamipide; nanoparticulated Rebamipide, propionate. The outcome measures included WHO mucositis grading, pain (NRS), ulcer size, healing time. data was analyzed for any statistical significance....
Hepatocellular carcinoma (HCC) is a dismal tumor with high incidence, prevalence and poor prognosis survival. Management of HCC necessitates multidisciplinary clinics due to the wide heterogeneity in its presentation, different therapeutic options, variable biologic behavior background presence chronic liver disease. We studied prognostic factors that affected survival our patients improve future management patient survival.This study performed specialized clinic for Kasr El Eini Hospital,...
Objective. Limited therapies are offered for large hepatocellular carcinoma (HCC). It carries dismal prognosis and efforts tried changing its management from a palliative to curative mode. Transarterial chemoembolization (TACE) is procedure that may have survival benefit if compared non-management of lesions. Microwave ablation (MWA) has emerged as relatively new technique with promise larger faster ablation. We aim evaluate the efficacy safety percutaneous MWA versus TACE tumors (5–7 cm)...
Introduction: Local ablative therapy and trans arterial chemoembolization (TACE) are applied to ablate non resectable hepatocellular carcinoma (HCC). Combination of both techniques has proven be more effective. We aimed study combined ablation assess survival benefit comparing TACE with radiofrequency (RFA) versus microwave (MWA) techniques. Methods: retrospectively studied 22 patients who were ablated using TACE-RFA 45 TACE-MWA. All classified as Child A-B lesions did not exceed 5 cm in...
Scarce reports have commented on hepatocellular carcinoma (HCC) behavior after direct-acting antivirals (DAAs).To analyze differences in tumor between patients with hepatitis C virus (HCV)-induced HCC and were either treated or not using DAAs.This case-control study includes HCV-related who received generic DAAs (group I) all non-DAA presented to our clinic during the same period II). Patient characteristics, treatment types outcome compared two groups.Group I included 89 group II 207...
A recent appearance of direct-acting antivirals (DAAs) led to a surge in hepatitis C virus (HCV) management. Nowadays, large proportion treated patients have cirrhosis with retained possibility develop hepatocellular carcinoma (HCC) even after complete cure. We aimed study tumoral differences between who developed HCC DAAs as either recurrence or de-novo HCC.We retrospectively analyzed 89 presented our multidisciplinary clinic lesions following DAA therapy. total 45 had response according...
Blockade of the programmed cell death-1/programmed death ligand-1 (PD-1/PD-L1) immune checkpoint pathway is an efficient immunotherapeutic modality that provided significant advances in cancer treatment especially solid tumors highly resistant to traditional therapy. Monoclonal antibodies (mAbs) and small-molecule inhibitors are two main strategies used block this axis with mAbs suffering from many limitations. Accordingly, current alternative development PD-1/PD-L1 inhibitors. Here, we...
Hepatocellular carcinoma (HCC), the fourth most common cancer in Africa, has a dismal overall survival of only 3 months like sub-Saharan Africa. This is affected by low gross domestic product and human development index, absence coherent guidelines, other factors.
Abstract The distribution of hepatitis C virus (HCV) genotypes was evaluated in individuals with hepatocellular carcinoma (HCC) and cirrhosis Egypt. A total 206 patients sero‐positive for HCV‐RNA among 400 surveyed (186 HCC, 100 cirrhosis, 114 healthy volunteers) were analyzed HCV genotype. Of patients, 129 had 65 without 12 volunteers. Phylogenetic analysis sequence showed that samples, 186 contained genotype 4 (90.3%), while 20 1 (9.7%). Among subjects 4, subtype 4a predominant (79%),...
The purpose of this study was to assess the role dynamic contrast enhanced and diffusion MR imaging in detection tumor viability after radiofrequency microwave ablation therapy hepatocellular carcinoma. done on 50 patients with HCC underwent or ablation. Patients were classified into resolved group if there's no MRI evidence at ablated lesion unresolved viability. In early 1 month post-ablation period, heterogenous signal zone precontrast T1 T2 images noted that gradually become more...
Schistosoma mansoni infection (SMI) is suspected to be directly and indirectly involved in hepato-carcinogenesis. This study evaluated the association of a previous SMI with hepatocellular carcinoma (HCC) development, patients, tumor characteristics, treatment outcomes, survival. observational included patients HCC without who presented multidisciplinary clinic, Kasr-Alainy hospital (November 2009 December 2019). It also 313 liver cirrhosis HCC. Clinical laboratory features (complete blood...
Combined pegylated interferon-α and ribavirin therapy has sustained virological response (SVR) rates of 54% to 61%. Pretreatment predictors SVR interferon have not been fully investigated yet. The current study assesses a group chemokines that may predict treatment in Egyptian patients with chronic HCV infection. CXCL5, CXCL9, CXCL11, CXCL12, CXCL 13, 16 E-Cadherin were assayed 57 patients' sera using quantitative ELISA plate method. All studied scheduled for combined alpha (32 received α...